Development and Validation of an Immunotherapy-Related Prognostic Signature Based on Lymph Node Ratio for Gastric Cancer

Figure 5

Evaluation and external validation of the prognostic signature in predicting overall survival of GC. (a) The Kaplan–Meier survival analysis of the signature for predicting the overall survival of GC patients in TCGA cohort. (b) The distribution of the risk score and the survival status of GC patients in TCGA cohort. (c) Univariate Cox regression of risk score and clinical parameters of GC in TCGA cohort. (d) Multivariate Cox regression of risk score and clinical parameters of GC in TCGA cohort. (e) The Kaplan–Meier survival analysis of the signature for predicting the overall survival of GC patients in GEO cohort. (f) The distribution of the risk score and the survival status of GC patients in GEO cohort. (g) Univariate Cox regression of risk score and clinical parameters of GC in GEO cohort. (h) Multivariate Cox regression of risk score and clinical parameters of GC in GEO cohort.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)